--The business combination of two AI-powered drug discovery and development companies, Recursion and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were sinking 8.2% lower as of 10:57 a.m. ET on Monday. The clinical-stage biotech company, which is a pioneer in using artificial intelligence ...

Recursion Pharmaceuticals is now the sole owner of a drug in its pipeline. The deal de-risks the company's pipeline by removing uncertainty; however, there's still a long way to go before REV102 ...

This week on STAT's podcast The Readout LOUD, hear about Biomarin's new chief business officer, Recursion's AI bona fides, and new findings on a GLP-1 and diabetes risk.

Recursion Pharmaceuticals (NasdaqGS:RXRX) saw its stock price increase by 12% over the past week. This movement could be associated with several recent developments. The company announced a ...

Recursion has stumbled through an early test of its tech-enabled drug discovery, reporting a hit on safety but failing to wow on the efficacy front.

With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbioSALT LAKE CITY, Nov. 09, 2023 ...

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy ...

Recursion Pharmaceuticals said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding crunch and the current policy uncertainty.